Inidascamine

Inidascamine is an experimental drug which is under development for the treatment of cognitive impairment associated with schizophrenia. It is taken orally. The drug is said to act on the cholinergic, NMDA, and GABA_B receptor systems. Inidascamine is being developed by Recognify Life Sciences and atai Life Sciences. It was discovered via screening of compounds for effects on synaptic plasticity and cognition. The drug shows structural similarities to phenethylamines and amphetamines.